FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2245584955> ?p ?o ?g. }

• W2245584955 endingPage "5034" @default.
• W2245584955 startingPage "5034" @default.
• W2245584955 abstract "5034 Background: Approximately 50% of ovarian tumors have copy number increases in chromsome20q. The 20q ovarian amplicon has yet to be precisely mapped, but is known to include part of 20q12 and 20q13. Elongation Factor 1 alpha 2 gene (EEF1A2) maps to 20q13.3 and encodes protein elongation factor 1 alpha 2 (eEF1A2). eEF1A2 mRNA is not detectable in normal ovarian epithelium but may be aberrantly expressed in human ovarian tumors. This overexpression might lead to an inhibition of apoptosis, a process that could plausibly contribute to neoplastic progression. The aim of this study was to examine the expression of EEF1A2 in epithelial ovarian cancer (EOC), and correlate with clinico-pathologic characteristics. Methods: One step RT-PCR was performed with cDNA from various normal tissues, with mRNA from 91 epithelial ovarian tumor tissues. eEF1A2 specific PCR product was amplified using eEF1A2 specific primers. GAPDH specific PCR amplification was used as control. The χ2 test was used to analyze the distribution of eEF1A2 expression and clinico-pathologic variables (stage, residual tumor, recurrence, disease free interval, and overall survival). Survival probabilities were estimated by Kaplan-Meier method. Results: Low level eEF1A2 m-RNA expression was restricted only to the normal tissues of the heart, brain, and skeletal muscle. eEF1A2 was not seen in normal ovarian tissue. eEF1A2 m-RNA expression was demonstrated in 21/91 (23%) of the ovarian cancer specimens. The median follow-up for the patient population was 23 months. There was a correlation between eEF1A2 expression and recurrence risk (likelihood ratio 6.9; p=0.03). The difference in median survival for eEF1A2 positive and negative patients was not statistically significant. Kaplan-Meier analysis indicates eEF1A2 expression to be a non-significant predictor of overall survival. Conclusions: Our data demonstrates that eEF1A2 is expressed at moderate frequency in patients with EOC. eEF1A2 expression also appears to be associated with increased risk for recurrence of disease. This data provides a new potential prognostic marker and oncogene for EOC, and may lead to the study of eEF1A2 as a suitable target for anticancer targeted therapy. No significant financial relationships to disclose." @default.
• W2245584955 created "2016-06-24" @default.
• W2245584955 creator A5030467056 @default.
• W2245584955 creator A5045548671 @default.
• W2245584955 creator A5089932011 @default.
• W2245584955 date "2005-06-01" @default.
• W2245584955 modified "2023-10-16" @default.
• W2245584955 title "The oncogene elongation factor 1 alpha-2 mRNA expression in epithelial ovarian cancer" @default.
• W2245584955 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.5034" @default.
• W2245584955 hasPublicationYear "2005" @default.
• W2245584955 type Work @default.
• W2245584955 sameAs 2245584955 @default.
• W2245584955 citedByCount "1" @default.
• W2245584955 crossrefType "journal-article" @default.
• W2245584955 hasAuthorship W2245584955A5030467056 @default.
• W2245584955 hasAuthorship W2245584955A5045548671 @default.
• W2245584955 hasAuthorship W2245584955A5089932011 @default.
• W2245584955 hasConcept C104317684 @default.
• W2245584955 hasConcept C121608353 @default.
• W2245584955 hasConcept C142724271 @default.
• W2245584955 hasConcept C153911025 @default.
• W2245584955 hasConcept C2780084626 @default.
• W2245584955 hasConcept C2780427987 @default.
• W2245584955 hasConcept C2781018059 @default.
• W2245584955 hasConcept C29537977 @default.
• W2245584955 hasConcept C49105822 @default.
• W2245584955 hasConcept C502942594 @default.
• W2245584955 hasConcept C54355233 @default.
• W2245584955 hasConcept C71924100 @default.
• W2245584955 hasConcept C8185291 @default.
• W2245584955 hasConcept C86803240 @default.
• W2245584955 hasConceptScore W2245584955C104317684 @default.
• W2245584955 hasConceptScore W2245584955C121608353 @default.
• W2245584955 hasConceptScore W2245584955C142724271 @default.
• W2245584955 hasConceptScore W2245584955C153911025 @default.
• W2245584955 hasConceptScore W2245584955C2780084626 @default.
• W2245584955 hasConceptScore W2245584955C2780427987 @default.
• W2245584955 hasConceptScore W2245584955C2781018059 @default.
• W2245584955 hasConceptScore W2245584955C29537977 @default.
• W2245584955 hasConceptScore W2245584955C49105822 @default.
• W2245584955 hasConceptScore W2245584955C502942594 @default.
• W2245584955 hasConceptScore W2245584955C54355233 @default.
• W2245584955 hasConceptScore W2245584955C71924100 @default.
• W2245584955 hasConceptScore W2245584955C8185291 @default.
• W2245584955 hasConceptScore W2245584955C86803240 @default.
• W2245584955 hasIssue "16_suppl" @default.
• W2245584955 hasLocation W22455849551 @default.
• W2245584955 hasOpenAccess W2245584955 @default.
• W2245584955 hasPrimaryLocation W22455849551 @default.
• W2245584955 hasRelatedWork W2004027931 @default.
• W2245584955 hasRelatedWork W2033138191 @default.
• W2245584955 hasRelatedWork W2042520059 @default.
• W2245584955 hasRelatedWork W2055795193 @default.
• W2245584955 hasRelatedWork W2144954214 @default.
• W2245584955 hasRelatedWork W2772993264 @default.
• W2245584955 hasRelatedWork W2792929645 @default.
• W2245584955 hasRelatedWork W2811173112 @default.
• W2245584955 hasRelatedWork W3110518147 @default.
• W2245584955 hasRelatedWork W4291227947 @default.
• W2245584955 hasVolume "23" @default.
• W2245584955 isParatext "false" @default.
• W2245584955 isRetracted "false" @default.
• W2245584955 magId "2245584955" @default.
• W2245584955 workType "article" @default.